Summary of ARS Pharmaceuticals Conference Call Company Overview - **Company**: ARS Pharmaceuticals (NasdaqGM:SPRY) - **Product**: Neffy, the first FDA-approved needle-free epinephrine nasal spray Key Goals for 2026 - **Access Expansion**: Aim to achieve around 90% coverage by summer 2026, focusing on securing larger payers for unrestricted access [5][6] - **Medicaid Coverage**: Anticipate onboarding several Medicaid states, with Florida expected to be next [6] - **Phase 2b Study on Urticaria**: Ongoing study with plans for interim analysis by summer 2026, which may be significant due to previous positive results [7][8] Commercial Strategy - **Get Neffy on Us Program**: Aims to alleviate physician burden from prior authorizations (PAs) by providing virtual prescription options [11][12] - **Patient and Caregiver Burden**: The program simplifies the process for patients, reducing wait times for prescriptions [16][18] Market Dynamics - **Epinephrine Market**: Approximately 50-60% of the market consists of refills due to expiration, with a significant portion of prescriptions being filled virtually [22][24] - **Neffy Uptake**: 75% of neffy users are switching from auto-injectors, while 25% are new patients who previously did not fill prescriptions [30][32] Coverage and Awareness - **Commercial Coverage**: 57% of covered lives have unrestricted access, with 93% overall coverage including those requiring PAs [43][44] - **Direct-to-Consumer (DTC) Campaign**: Increased consumer awareness from 20% to over 60%, with a focus on the benefits of neffy [47][48] Partnership Insights - **ALK Partnership**: Positive relationship with ALK-Abelló, with successful launches in Europe, particularly in Germany and the UK, where neffy has gained significant market share [55][56] Urticaria Study Insights - **Potential Market**: Neffy could serve as an effective treatment for urticaria flares, with a focus on low-dose administration to minimize side effects [64][66] - **Economic Argument**: Potential to reduce emergency room visits, making it appealing to insurance companies [65] Future Outlook - **Manufacturing Expansion**: Plans for a second manufacturing site in Europe and potential site in China to support market growth [78] - **Market Underappreciation**: The food allergy market and the value of the urticaria indication are seen as underrecognized opportunities [79][80] Conclusion - ARS Pharmaceuticals is strategically positioned to expand its market presence with neffy, focusing on access, awareness, and innovative treatment options for both food allergies and urticaria. The company is optimistic about its growth trajectory and the potential impact of its products on patient care.

Financial Data and Key Metrics Changes - For the full year 2025, total revenue was $84.3 million, consisting of $72.2 million in U.S. net product revenue, $9.7 million from collaboration agreements, and $2.4 million in supply revenue from international partners [19][20] - R&D expenses were $13.2 million, while SG&A expenses reached $230.1 million, reflecting significant investment in commercialization efforts [20][21] - The company ended 2025 with a cash balance of $245 million, providing a strong financial position for ongoing commercial expansion [22] Business Line Data and Key Metrics Changes - The neffy product generated $72.2 million in net product revenue during its first full year of commercial sales, indicating strong market penetration [3][19] - Approximately 93% of commercial coverage was achieved by year-end 2025, with 57% of covered lives having access without prior authorization [8][12] Market Data and Key Metrics Changes - The company reported that 90% of patients experiencing anaphylaxis are effectively treated with a single dose of neffy, supporting its profile as a reliable treatment [3] - Aided awareness of neffy increased from approximately 20% pre-campaign to 60% by year-end 2025, indicating successful direct-to-consumer marketing efforts [14] Company Strategy and Development Direction - The company plans to expand its sales force from 106 to 150 representatives in 2026, funded through reallocating existing resources rather than increasing overall SG&A expenses [6][21] - The focus for 2026 will be on access, adoption, and advancement, with efforts to reduce administrative barriers and improve workflow integration for prescribers [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the neffy product's potential, emphasizing the need for continued education and engagement with healthcare providers [4][24] - The company anticipates that as the installed patient base matures, renewal contributions will become increasingly relevant starting in late 2026 [8][18] Other Important Information - The company is advancing its pipeline for chronic spontaneous urticaria, with interim data expected in the second half of 2026 [9] - The gross-to-net retention rate was in the low to mid 50% range, with expectations for greater predictability in revenue modeling as coverage broadens [22] Q&A Session Summary Question: How are you thinking about inventory dynamics in 1Q and into 2Q? - Management indicated they are comfortable with current inventory levels and will monitor closely as the back-to-school season approaches [26][27] Question: How are you looking at the direct-to-consumer spend in 2026? - The company expects direct-to-consumer spending in 2026 to be similar to 2025, around $100 million [30] Question: Can you provide more color on the contribution from the Get neffy program? - Currently, over 10% of prescriptions are coming through the Get neffy program, which is expected to grow as awareness increases [34] Question: Can you elaborate on the funding for the sales force expansion? - Funding for the sales force expansion will come from reallocating budgets from advertising and market research [45][51] Question: What are you seeing from the direct-to-consumer campaign beyond awareness? - The campaign has shown strong advertisement recall and positive feedback on messaging, indicating it resonates well with consumers [55][56] Question: How should we think about the timing and cadence of refills? - Most prescriptions are currently new, but refill dynamics are expected to pick up significantly by the end of 2026 as initial prescriptions expire [60][64]

NASDAQ: SPRY neffy – the transformative needle -free solution for severe allergic reactions March 2026 Corporate Presentation Forward-looking statements Statements in this presentation that are not purely historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the potential market, demand and expansion opportunities for neffy; the belief ...

Summary of Nasus Pharmaceuticals Conference Call Company Overview - **Company**: Nasus Pharmaceuticals - **Industry**: Clinical-stage pharmaceutical company focused on intranasal products for acute medical conditions - **Key Product**: NS002, an intranasal powder epinephrine product for anaphylaxis, designed as a needle-free alternative to EpiPen [1][3] Core Points and Arguments - **Product Development**: - NS002 is being developed to provide rapid and reliable drug delivery using proprietary powder-based intranasal technology [1][3] - The product aims to address the limitations of EpiPen, including needle phobia and bulkiness [7][9] - Nasus has a robust pipeline with additional products in development, including ondansetron for chemotherapy-induced nausea and two undisclosed products in metabolic and cardiovascular spaces [4][24] - **Market Opportunity**: - The anaphylaxis market is valued at approximately $2.5 billion annually, expected to grow to $4-5 billion due to rising allergy incidences [9][10] - There are about 20 million patients in the U.S. with severe Type I allergies, yet only one-third have a prescription for EpiPen, indicating a significant market opportunity for needle-free alternatives [10][11] - **Clinical Performance**: - NS002 has demonstrated superior absorption and pharmacokinetic properties compared to EpiPen, including the shortest Tmax (time to maximal concentration) and T100 (time to reach 100 picograms of epinephrine) [12][13] - In clinical studies, 91% of subjects achieved the 100 picogram threshold at 5 minutes, compared to 67% for EpiPen [14][19] - The product has shown consistent performance even under nasal allergic challenge conditions, maintaining effective absorption levels [16][20] - **Safety and Tolerability**: - The product was well tolerated with no serious adverse events reported, and most adverse events were mild and self-resolving [21][22] - Local side effects were primarily related to the nasal administration, while systemic side effects were comparable to EpiPen [22] Additional Important Content - **Intellectual Property**: Nasus holds a broad patent portfolio covering its powder technology and individual products, with patents extending to 2038 [22] - **Financial Position**: The company is fully funded through the NDA submission planned for mid-2027, supported by recent PIPE financing [32] - **Market Dynamics**: There is a growing trend towards needle-free epinephrine products, with historical precedents in other therapeutic categories showing rapid market shifts towards such alternatives [29][30] Conclusion - Nasus Pharmaceuticals is positioned to capitalize on the growing demand for needle-free epinephrine products, with a strong clinical pipeline and favorable pharmacokinetic data supporting its lead product, NS002. The company is well-funded and has a clear strategy to navigate the competitive landscape, aiming to establish itself as a leader in the anaphylaxis treatment market [24][25]

Core Insights - ALK's full-year results for 2025 exceeded expectations, driven by strong Q4 performance and ongoing commercial momentum [1] - The company anticipates sustained organic revenue growth of 11-15% and an EBIT margin of around 25% by 2026, aligning with long-term targets [1][14] - A dividend payment of DKK 355 million, approximately 30% of net profit after tax, is recommended to reward shareholders [1][6] Financial Performance - Q4 2025 revenue reached DKK 1,733 million, a 17% increase compared to the previous year, while full-year revenue grew by 15% to DKK 6,312 million [3][4] - EBIT for Q4 increased by 88% to DKK 387 million, with a margin of 22%, and for the full year, EBIT rose by 53% to DKK 1,654 million, achieving a margin of 26% [3][4] - Free cash flow was positive at DKK 1,432 million, significantly improved from a negative DKK 204 million the previous year [4] Product Performance - Tablet sales increased by 15% to DKK 910 million in Q4, with notable growth in Europe and North America [4] - Sales of SCIT/SLIT drops rose by 11% to DKK 607 million, while anaphylaxis and other products saw a 50% increase to DKK 216 million [4] - Pediatric launches of ACARIZAX and ITULAZAX exceeded expectations, with strong prescriber adoption [5] Strategic Outlook - The company plans to continue double-digit revenue growth and higher earnings in 2026, with a focus on treating more patients with AIT and anaphylaxis products [7][8] - The EBIT margin may experience slight pressure due to a decline in gross margin, offset by higher partner-related sales at lower margins [8] - Ongoing partnerships and clinical trials are expected to contribute positively to future growth [5]

Financial Data and Key Metrics Changes - For Q4 2025, reported sales increased by 14% to $963 million, up from $848 million in the prior year, while core sales grew by 5% [3][4] - Full-year reported sales rose by 5% to $3.8 billion, compared to $3.6 billion in the previous year, with core sales up by 2% [5][24] - Reported net income increased by 5% to $393 million, and reported earnings per share grew by 7% to $5.89, up from $5.53 a year ago [5][24] - Adjusted earnings per share were $5.74, a slight decline of 1% compared to the prior year [6][24] - Adjusted EBITDA margin for Q4 was approximately 19.8%, down from 23% in the prior year [17][24] Business Line Data and Key Metrics Changes - Pharma segment core sales increased by 4%, with prescription core sales up by 1% and consumer healthcare core sales up by 3% [17][18] - Injectables core sales surged by 24%, driven by strong demand for elastomeric components [18] - Beauty segment core sales increased by 10%, with personal care core sales rising by 17% [19][20] - Closures segment core sales increased by 1%, with beverage core sales up by 7% [21] Market Data and Key Metrics Changes - Strong demand was noted in the pharma segment, particularly for systemic nasal drug delivery and injectables [4][8] - The beauty segment experienced double-digit growth across fragrance and facial skincare markets [4][19] - The closures segment saw volume growth, although impacted by lower resin pricing [21] Company Strategy and Development Direction - The company is focusing on cost reduction initiatives and back-office centralization through global talent centers [4][29] - There is an emphasis on productivity measures and efficiency improvements, with expectations for continued growth in the pharma segment excluding emergency medicine [30][28] - The company aims to maintain a disciplined approach to capital allocation while investing in long-term growth opportunities [6][25] Management's Comments on Operating Environment and Future Outlook - Management anticipates near-term headwinds in emergency medicine extending through 2026, with a revenue headwind of approximately $65 million expected [26] - The company expects steady improvements in beauty margins and overall performance in the second half of 2026 [34][39] - There is confidence in the growth potential of the pharma segment, particularly in injectables and systemic nasal drug delivery technologies [30][45] Other Important Information - The company returned $486 million to shareholders in 2025 through share repurchases and dividends, marking its 32nd consecutive year of increasing dividends [6][25] - The company issued $600 million of senior notes in Q4 2025 to support its capital structure [23] Q&A Session Summary Question: Is there any deceleration in GLP-1 demand in elastomers in 2026? - Management expects injectables to grow in the high single digits to low double digits, with GLP-1 being an important but not sole driver of growth [32][33] Question: What is the expectation for EBITDA margin trends throughout the year? - Margins are expected to improve significantly in the second half of the year, driven by increased volume and productivity measures [34] Question: Can you elaborate on the margin performance in beauty and closures? - Operational issues and environmental upgrades impacted margins, but improvements are expected as these issues are resolved [39][40] Question: What is the outlook for emergency medicine sales? - Emergency medicine is expected to face challenges, with a significant decline anticipated in the first half of 2026 [26][41] Question: How does the company view the growth potential for Narcan and cough and cold products? - Management sees low to mid-single-digit growth for Narcan and anticipates a strong cough and cold season, with updates expected in Q1 and Q2 [46][48]

Core Viewpoint - ALK has received a positive opinion from the CHMP recommending the marketing authorisation for EURneffy, a 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older [1][2][3] Group 1: Product Development and Authorisation - The positive CHMP opinion supports an extension to the existing marketing authorisation for EURneffy 2 mg, which was granted in August 2024 for adults and children weighing ≥30 kg [2] - The marketing authorisation for EURneffy 1 mg, if approved, will be valid across all EU member states, as well as Iceland, Liechtenstein, and Norway [3] Group 2: Market Context and Impact - Anaphylaxis is a severe allergic reaction requiring immediate medical intervention, with an incidence rate of approximately 1 in 761 children in Europe each year [4] - Foods are the most common trigger for anaphylaxis in children, accounting for over two-thirds of cases, with increasing hospitalisations due to food allergies [4] Group 3: Strategic Partnerships - ALK entered into a strategic license agreement with ARS Pharmaceuticals in November 2024, granting exclusive global rights to commercialise neffy, excluding the USA, Australia, New Zealand, Japan, and China [5] - The partnership was extended in May 2025 to include a co-promotion agreement in the USA [5] Group 4: Company Overview - ALK is a global specialty pharmaceutical company focused on allergy, covering the entire value chain from development to marketing of products for diagnosing and treating respiratory allergies and severe allergic reactions [8] - The company is headquartered in Denmark and employs around 2,700 people worldwide, listed on Nasdaq Copenhagen [8]

Group 1 - ARS Pharmaceuticals Inc. stock increased by 18.86% to $13.01 following a negative update regarding its competitor, Aquestive Therapeutics Inc. [5] - The FDA identified deficiencies in Aquestive's Anaphylm's New Drug Application, which delays discussions on labeling and post-marketing commitments [1] - This situation allows ARS Pharmaceuticals to establish its needle-free epinephrine device, neffy, as the only option in the market for the time being [2] Group 2 - ARS Pharmaceuticals filed a petition urging the FDA to delay approval of Aquestive's AQST-109, citing safety and efficacy concerns [3] - The company argues that current data do not sufficiently demonstrate the drug's safety or efficacy for anaphylaxis patients and requests additional studies [4] - Analysts see significant potential for neffy and believe the company is well-funded to support its launch [4]

Core Insights - ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is recognized by Wall Street analysts as one of the stocks expected to rebound, with Roth MKM maintaining a Buy rating and a price target of $30 for the stock [1] Group 1: Regulatory Approvals and Product Launch - The National Medical Products Administration (NMPA) in China has approved neffy 2 mg, an epinephrine nasal spray, for emergency treatment of Type 1 allergic reactions and anaphylaxis, applicable to adults and children weighing at least 30 kilograms [2] - ARS Pharmaceuticals has an exclusive licensing agreement with Pediatrix Therapeutics for the commercialization of neffy in China, which includes a final regulatory milestone payment of $4 million and potential additional sales-based milestone payments of up to $80 million [3] - The company will manufacture and supply neffy to Pediatrix in China at cost and expects the product to be available in the spring of 2026 [4] Group 2: Future Plans and Market Strategy - ARS Pharmaceuticals and Pediatrix plan to file for approval of a neffy 1 mg dose for children weighing more than 15 kilograms and less than 30 kilograms in the upcoming months [4] - The company is focused on developing treatments for allergies that could lead to anaphylaxis, indicating a strategic emphasis on addressing severe allergic reactions [5]

FDA Approvals & Rejections - ARS Pharma's neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, received approval in China, with commercial availability expected in spring 2026. The product generated $31.3 million in U.S. revenue in Q3 2025 [3][4]. - Vanda Pharmaceuticals' NEREUS, an oral NK-1 receptor antagonist for preventing motion-induced vomiting, received FDA approval, marking the first new treatment for motion sickness in over 40 years. The drug demonstrated a meaningful reduction in vomiting in clinical trials [5][6]. Clinical Trials - Breakthroughs & Setbacks - InflaRx's analyses from a halted Phase 3 trial of Vilobelimab in pyoderma gangrenosum indicated potential efficacy signals with longer treatment duration, prompting plans to discuss alternative endpoints with the FDA [15][17]. - SELLAS reported that survival in its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukaemia is extending longer than anticipated, potentially increasing the likelihood of a positive outcome [18][19]. - Ultragenyx announced that its Phase 3 studies for Setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, leading to a decline in investor confidence [20][21]. - Genmab decided to discontinue clinical development of Acasunlimab to focus on higher-priority programs, with no impact expected on its full-year 2025 financial guidance [22][23]. Corporate Actions - FONAR Corporation agreed to be taken private by a CEO-led acquisition group for $19.00 per share, valuing the transaction at a significant premium. The deal is expected to close in Q3 2026, subject to shareholder approval [12][13][14].